Protocol Ledger

NCT04993768 · Phase II · COMPLETED

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Interventional Phase II clinical trial protocol NCT04993768 sponsored by Transposon Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-12 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04993768
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04993768
Protocol FieldVerified Registry Value
NCT IdentifierNCT04993768
Consolidated Lead SponsorTransposon Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2021-12-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI